Glucophage generic
Pro Research Analysisby 
Searched over 200M research papers for "glucophage generic"
Consensus Meter
Glucophage Generic: Efficacy, Safety, and Bioequivalence
Introduction to Metformin and Glucophage
Metformin, a biguanide derivative, is a widely used antihyperglycemic agent for managing type 2 diabetes mellitus (T2DM). The original brand, Glucophage®, introduced by Bristol-Myers Squibb, has been the benchmark for metformin formulations. With the advent of generic versions, it is crucial to evaluate their bioequivalence, efficacy, and safety compared to the innovator drug.
Bioequivalence of Generic Metformin Formulations
Sustained-Release Metformin (MH-SR) Tablets
A study conducted on healthy Chinese volunteers compared the bioequivalence and safety of generic metformin hydrochloride sustained-release (MH-SR) tablets (Boke®) with Glucophage®-XR. The results indicated that the generic MH-SR tablets were bioequivalent to Glucophage®-XR, with the 90% confidence intervals for key pharmacokinetic parameters falling within the acceptable range of 80.00–125.00%. This study supports the use of generic MH-SR tablets as a viable alternative to Glucophage®-XR in the Chinese market.
Immediate Release Metformin (IR) Tablets
Another study compared the efficacy and safety of Volv® (Metformin IR) with Glucophage® (Metformin IR) in Taiwanese patients with T2DM. Both formulations showed significant reductions in HbA1c and fasting plasma glucose (FPG) levels over a 5-month period, with no significant differences in therapeutic outcomes or adverse events between the two groups. This suggests that Volv® is as effective and safe as Glucophage® for managing T2DM.
Clinical Efficacy and Safety
Comparison of Dulening and Glucophage
A large-scale clinical trial involving 886 patients with T2DM compared the efficacy and safety of Dulening metformin SR tablets with Glucophage. Both groups exhibited similar reductions in HbA1c and fasting blood glucose levels after 12 weeks of treatment. However, the Dulening group had a significantly lower incidence of adverse drug reactions (ADRs), particularly gastrointestinal ADRs, compared to the Glucophage group. This indicates that Dulening metformin SR tablets are not only effective but also better tolerated than Glucophage.
Generic Metformin in Different Markets
A study assessing the quality control parameters and in vitro bioequivalence of various metformin brands in Nigeria found that several generic formulations were bioequivalent to Glucophage. Brands such as Diaphage®, Diamet®, and Glucomet showed similar dissolution profiles and were deemed interchangeable with Glucophage. This highlights the potential for using generic metformin products in different regions without compromising efficacy or safety.
Pharmacological End Point Evaluation
A pharmacological study comparing Metphage (a generic metformin) with Glucophage found no significant differences in the hypoglycemic effects produced by the two formulations. Both were well-tolerated, with no hypoglycemic episodes requiring medical intervention. This further supports the interchangeability of generic metformin with the innovator drug.
Conclusion
The body of research indicates that various generic formulations of metformin, including sustained-release and immediate-release tablets, are bioequivalent to the original Glucophage. These generics demonstrate comparable efficacy and safety profiles, making them suitable alternatives for managing type 2 diabetes mellitus. The availability of effective and safe generic options can help meet market demands and provide cost-effective treatment solutions for patients worldwide.
Sources and full results
Most relevant research papers on this topic